Anjali Vaidya, MD, FACC, FASE, FACP, Director of the Advanced Pulmonary Hypertension, Right Heart Failure and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program at Temple University Hospital, offered insight to MedPage Today on findings from the HYPERION trial, the long-awaited study of Sotatercept in pulmonary arterial hypertension (PAH) within one year after initial diagnosis. The findings were presented at the ERS Congress and simultaneously published in the New England Journal of Medicine. Dr. Vaidya was not involved in the trial.
IMPORTANT: Labor & Delivery services have moved from Temple University Hospital–Main Campus (Broad & Ontario) to our new women & families hospital.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH